Skip to main
PODD

Insulet (PODD) Stock Forecast & Price Target

Insulet (PODD) Analyst Ratings

Based on 21 analyst ratings
Buy
Strong Buy 38%
Buy 19%
Hold 38%
Sell 5%
Strong Sell 0%

Bulls say

Insulet is a Neutral rating and shares are fairly valued on an EV/sales basis. The company's overreliance on the Omnipod system, which makes up over 98% of their revenue, exposes them to potential cybersecurity risks and recalls, as well as fierce competition in the insulin delivery market. While the recently released Omnipod 5 system may provide a boost to international sales, lower rates of utilization and retention among Type 2 customers in the US could hinder growth for the remainder of the year. Additionally, management credibility has been called into question due to recent missteps and recalls, leaving the company's outlook uncertain and hindering potential for further growth and profitability.

Bears say

Insulet is facing increased pressure and competition from tubed pump competitors, new market entrants, and potential market risks and global inflationary trends. Their efforts to maintain their position as a market leader and increase revenue and margins through new product initiatives and expansion into the Type 2 diabetes market may not be enough to offset potential losses in market share and margin compression.

Insulet (PODD) has been analyzed by 21 analysts, with a consensus rating of Buy. 38% of analysts recommend a Strong Buy, 19% recommend Buy, 38% suggest Holding, 5% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Insulet and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Insulet (PODD) Forecast

Analysts have given Insulet (PODD) a Buy based on their latest research and market trends.

According to 21 analysts, Insulet (PODD) has a Buy consensus rating as of Sep 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $193.19, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $193.19, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Insulet (PODD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.